FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/Real-World Study Launches to Track Weight Loss and Well-being After Semaglutide Treatment for Severe Obesity
연구 도서관으로 돌아가기

Real-World Study Launches to Track Weight Loss and Well-being After Semaglutide Treatment for Severe Obesity

November 20, 2026
Share
Emergent 연구

이 주제에 대한 잠재적인 결과가 있지만 추가 검증이 필요합니다. 이러한 발견은 유망하지만 확실하지 않습니다.

이 분석에 대해 알아보기

이 기사는 AI 도구를 사용하여 생성된 요약입니다. 최근 게시된 뉴스 항목이나 임상 시험 목록의 요약으로, 피테이드 연구 커뮤니티에게 빠르고 접근하기 쉬운 개요를 제공하기 위해 작성되었습니다. 정확성을 위해서는 항상 아래 링크로 연결된 원문을 참조하십시오.

Real-World Study Launches to Track Weight Loss and Well-being After Semaglutide Treatment for Severe Obesity

A new real-world follow-up study has been launched in France to evaluate the long-term impact of semaglutide treatment on individuals with severe obesity. The SEMAFOLLOW study, registered under ClinicalTrials.gov as NCT07423481, aims to gather detailed information about weight trajectories and predictive factors for patients who have undergone treatment with WEGOVY® (semaglutide 2.4 mg). This research is crucial for understanding the effectiveness of peptide therapy in managing severe obesity.

Background

Obesity is a complex condition that affects millions of people worldwide, leading to numerous health complications such as cardiovascular disease and diabetes. In recent years, semaglutide has emerged as an effective treatment option for individuals struggling with weight management. Semaglutide works by mimicking the action of GLP-1 (glucagon-like peptide 1), a hormone that helps regulate blood sugar levels and promotes feelings of fullness.

In France, WEGOVY® is available under temporary authorisation for use (ATU) and an early access programme. This means that patients who meet specific criteria can receive the treatment before it has been fully approved by regulatory bodies like the FDA. The SEMAFOLLOW study seeks to gather data from these real-world settings to provide valuable insights into how semaglutide performs in a broader population.

Key Details

The SEMAFOLLOW study is being conducted by teams of specialists from various obesity centres across France, ensuring a comprehensive evaluation of treatment outcomes. Participants will be followed up over an extended period to track their weight changes, assess the effectiveness of different treatment strategies, and evaluate overall well-being. The study uses the SEMAFOLLOW questionnaire to gather detailed information about patients' experiences with semaglutide.

This research is particularly important because it focuses on individuals with grade 3 obesity (BMI ≥40 kg/m²) or those with obesity-related complications. These patients often face significant challenges in managing their weight and improving their health outcomes, making the findings from this study highly relevant for both clinicians and researchers working in the field of peptide therapy.

Key Takeaways

  • Comprehensive Evaluation: The SEMAFOLLOW study provides a detailed look at how semaglutide performs over time in real-world settings.
  • Patient-Centered Approach: By using the SEMAFOLLOW questionnaire, the study captures the patient's perspective on treatment effectiveness and well-being.
  • Focus on Severe Cases: This research targets individuals with grade 3 obesity or those with severe complications, offering insights that are directly applicable to high-risk patients.
  • Collaborative Effort: The involvement of multiple specialist teams ensures a thorough assessment of semaglutide's impact across different patient populations.

What This Means

For the peptide community, the SEMAFOLLOW study represents an important step forward in understanding the long-term benefits and challenges associated with semaglutide treatment. As more data becomes available from real-world applications, clinicians can make better-informed decisions about which patients might benefit most from this therapy. Additionally, researchers will have valuable information to guide future studies on peptide therapies for obesity management.

The findings from SEMAFOLLOW could also influence regulatory discussions around the approval and use of semaglutide in other regions, including potential FDA regulation updates. This study underscores the importance of ongoing research into peptide-based treatments as a cornerstone of modern weight management strategies.

---

Source: ClinicalTrials.gov — Published 2026-11-19

This article is for informational purposes only and does not constitute medical advice.

편집자의 주석

이 분석은 AI 도구를 사용하여 생성되었으며 Peptide Contacts 편집팀으로부터 검토되었습니다. 정확성을 위해 항상 원문을 참조하십시오. 원본 출처 전체 세부사항, 방법론 및 데이터는 여기에서 확인하실 수 있습니다.

Peptide Contacts는 정보 제공 목적으로만 피테이드 연구 요약을 큐레이션합니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 건강 결정을 내릴 때 항상 자격 있는 의료 전문가와 상담하십시오.

Comments

Sign in to join the discussion

이 기사는 AI 도구를 사용하여 생성되었으며 정확성을 보장하지 않습니다. 정보 제공 목적으로만 제공되며 의학적 조언으로 간주되지 않습니다. 항상 원문을 참조하고 자격 있는 의료 전문가와 상담하십시오.